Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

RNACCartesian TherapeuticsRunning, no new patients

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Myasthenia Gravis, Generalized

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • A key executive is leaving

    Since May 26, 2026 · was worth 15, fading over time

    +2.3
Worry score2

Score over time

Stage
Phase 2
Patients
30 (planned)
Started
Dec 4, 2019
Main results expected
Jan 5, 2026
Fully finished
Sep 30, 2026
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Proportion of patients with MG Composite improvement of ≥5 points.

    Measured over: Day 0 to Day 85

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • key_exec_departure: base 15, now 2.3, since 2026-05-26, fades (half-life) · source filing

Raw record changes

  • none yet

Trial ID NCT04146051 · record last updated 2026-08-14 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT04146051) ↗